Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

March 4 (Reuters) - Moderna (MRNA.O), opens new tab shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

European drug regulators recommended authorizing Moderna’s combined vaccine against Covid-19 and the flu, paving the way for the shot’s approval in the European Union at a time the company is facing ...

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

A vial containing Moderna's COVID vaccine. A deal related to the vaccine's patents clears the way for the pharma company's vaccine pipeline. Shares of Moderna on Wednesday surged to their highest in ...

Just over two months into 2026, Moderna has weathered a number of regulatory and financial storms that could have proven catastrophic. Moderna, which was already financially struggling, announced ...

The European Medicines Agency’s (EMA) drug review committee has taken a positive stance on granting marketing authorisation to Moderna’s combination Covid-19 and influenza vaccine, mCombriax ...